KIM, SU JEONG,NOH, SANG EUN,LEE, JUN HO,LEE, HYEON YOUL,CHOI, KYOUNG BAEK,CHOI, HEON SIK
申请号：
CA3068552
公开号：
CA3068552A1
申请日:
2018.06.29
申请国别(地区):
CA
年份:
2019
代理人:
摘要：
The present invention relates to a method for assessing validity of a cell therapy product. An expression level of TGF-ß and/or TSP-1 in: (a) a 1st population of mammal cells transformed with TGF-ß； and (b) a 2nd population of mammal cells not transformed with the gene and/or whether or not TGF-ß and/or TSP-1 is expressed in the populations can be used as a decision criteria for validity of cell therapy products according to the present invention to certainly determine the validity of individual cell therapy products before the start of treatment therewith, thereby allowing the maintenance of uniform therapeutic effects. In addition, the use of a cell therapy product with which no effects are obtained can be avoided, thus evading unnecessary treatment or side effects.
